NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Infinimmune

Infinimmune

Private
Alameda, CaliforniaHealthcare & Life Scienceshttps://www.infinimmune.com/

Last Round

Series A

Aug 11, 2026

Total Funding Raised

$87M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Infinimmune is a biotechnology company that develops human-derived antibody medicines by discovering antigen-specific antibodies from human B cells via proprietary sequencing and AI-guided engineering platforms.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Infrastructure

Keywords

antibody discoverydrug discoverybiotech platformAI drug discoveryantibody engineeringtherapeutic antibodiesin silico drug designGLIMPSEantibody language modelbiopharma R&Dprotein engineeringbiotechAI biocomputational biologypharma partnership

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Infinimmune Comparables

Compare Infinimmune with similar companies based on industry and business-model similarity.

Infinimmune comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BigHat Biosciences
87%
AbTherx, Inc.
84%
BioLoomics
84%

Infinimmune Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AAug 11, 2026
SeedDec 6, 2022

Key People

Founding team and executive leadership

Maria Grunwald

Advisor To Chief Executive Officer

Executive Team

Wyatt McDonnell

Co-Founder and CEO

Founding Team

Infinimmune Investors

Notable investors and investment history

Infinimmune investors
InvestorRounds
RA Capital ManagementSeries A
Playground GlobalSeed
Wild Tree VenturesSeries A
Pear VCSeed, Series A
Forge Life Science PartnersSeries A
Everbright BiofundSeries A
Goldcrest CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 11, 2026

    $75M round led by Playground Global and Regeneron Ventures.

  • Apr 27, 2026

    Anthony Slavin appointed as new SVP of Portfolio Strategy.

Infinimmune Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Infinimmune Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Infinimmune's valuation, stock price, and market status.

Firmographic Details

HeadquartersAlameda, California
Employee Range16
Year Founded2022
Last FundingAug 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.